PRT 062607

Drug Profile

PRT 062607

Alternative Names: BIIB-057; P 50515; PRT-2607; PRT062607; Syk inhibitor - Biogen

Latest Information Update: 19 Feb 2016

Price : $50

At a glance

  • Originator Portola Pharmaceuticals
  • Developer Biogen; Portola Pharmaceuticals
  • Class Antineoplastics; Antirheumatics; Nonsteroidal anti-inflammatories; Small molecules
  • Mechanism of Action Syk kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Cancer; Inflammation; Rheumatoid arthritis; Systemic lupus erythematosus
  • Phase Unknown Allergic asthma

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 29 Aug 2013 Portola Pharmaceuticals completes a phase I trial in healthy volunteers in USA
  • 10 Dec 2012 Investigation in Allergic asthma in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top